ARKG — ARK Genomic Revolution ETF
Healthcare Ranked #389 of 458 tracked ETFs · Issued by ARK ETF Trust
ARKG Price Performance — Growth of $10,000
Value of a $10,000 investment in ARKG over time, compared with SPY. Both lines are rebased to $10,000 on the first shared date. Based on total returns — prices are adjusted for dividends and splits, so this assumes distributions were reinvested. Hover or tap the chart for exact values.
ARKG Drawdown
The "underwater" chart: ARKG's decline from its highest prior value at each point in time. It shows how deep past losses ran and how long the fund took to recover to break-even.
What If You'd Invested in ARKG?
See what a lump sum in ARKG would have grown to, with the option to add a regular monthly contribution on top. Figures use total returns — dividends are assumed reinvested.
Past performance doesn't predict future results. Assumes contributions on the first trading day of each month, no trading costs or taxes, and reinvested distributions. History is limited to the range published in the site's daily return data.
Overview
The ARK Genomic Revolution ETF, issued by ARK ETF Trust, operates within the Healthcare category where ETFValuer tracks a total of 11 funds. This fund holds an overall rank of #389 out of 458 tracked ETFs across all categories and has received an ETFValuer grade of D with a score of 47.5 out of 100. It charges an expense ratio of 0.75% and currently offers a dividend yield of 0.00%. The fund trades at a price of $37.81 with assets under management totaling $1.73 billion. This asset size suggests a significant level of investor adoption relative to the broader universe of 458 tracked funds. The combination of a low grade and a mid-tier rank indicates mixed performance characteristics compared to the wider market.
Recent trading activity shows a decline of 2.60% over one day and a further drop of 5.17% over the past week. Despite these short-term losses, the fund posted a 2.00% gain over the last month and a substantial 26.88% increase over the past three months. Year-to-date returns have accelerated to +29.58%, while the one-year return stands at +42.41%. In contrast, the three-year return is negative at -0.50%, indicating a divergence between recent momentum and longer-term results. This pattern suggests a sharp recovery in the most recent periods following a prolonged period of underperformance over the multi-year horizon.
The fund carries a volatility label of Very High and exhibits a beta of 2.38, indicating it moves significantly more than the broader market. A Sharpe ratio of 0.87 suggests that the returns generated have not fully compensated for the high level of risk taken. The maximum drawdown recorded is -51.74%, reflecting severe potential losses during market downturns. This combination of a very high beta and a deep maximum drawdown implies the fund experiences extreme swings in both up and down markets. Investors face substantial risk of capital erosion during negative periods despite the high beta amplifying gains during rallies.
AI-generated summary based on the data on this page.
ARKG Top Holdings
| # | Holding | % of Net Assets | Value |
|---|---|---|---|
| 1 | TEMPUS AI INC | 9.42% | $116M |
| 2 | TWIST BIOSCIENCE CORP | 8.99% | $111M |
| 3 | CRISPR THERAPEUTICS AG | 8.91% | $110M |
| 4 | 10X GENOMICS INC | 5.77% | $71M |
| 5 | BEAM THERAPEUTICS INC | 5.43% | $67M |
| 6 | ABSCI CORP | 4.78% | $59M |
| 7 | NATERA INC | 4.07% | $50M |
| 8 | ILLUMINA INC | 4.03% | $50M |
| 9 | INTELLIA THERAPEUTICS INC | 3.82% | $47M |
| 10 | PERSONALIS INC | 3.58% | $44M |
Holdings as of 2026-04-30 per the fund's most recent SEC N-PORT-P filing. Top 10 holdings make up 58.8% of net assets — a rough gauge of concentration risk (the higher this figure, the more the fund's return depends on a handful of names). To see how ARKG's holdings overlap with other ETFs you own or are considering, check the Stock Overlap tool.
Which Funds Overlap With ARKG
Holding two funds that own the same companies adds cost and complexity without adding much diversification. These tracked ETFs share the most names with ARKG's top 10 — ARKK overlaps most, holding 2 of the same companies as ARKG's top 10 (18.3% of ARKG's assets).
| ETF | Name | Shared Companies | ARKG Weight | Examples |
|---|---|---|---|---|
| ARKK | ARK Innovation ETF | 2 | 18.3% | TEMPUS AI INC, CRISPR THERAPEUTICS AG |
| VB | Vanguard Small-Cap Index Fund ETF Shares | 1 | 4.1% | NATERA INC |
| VBK | Vanguard Small-Cap Growth Index Fund ETF Shares | 1 | 4.1% | NATERA INC |
Compares the top 10 reported holdings of each fund, so it's a floor on true overlap — two S&P 500 trackers overlap ~100% even when only 10 names are listed. Use the Stock Overlap tool to search by individual company.
Market Backdrop
10-Year Treasury Yield: 4.71% (as of 2026-07-23) — The yield on 10-year US Treasury bonds — the standard "risk-free rate" benchmark used to contextualize this fund’s Sharpe ratio and returns.
CBOE Volatility Index (VIX): 18.70 (as of 2026-07-23) — A real-time gauge of expected S&P 500 volatility over the next 30 days — useful context for this fund’s own volatility label.
Federal Funds Rate: 3.63% (as of 2026-06-01) — The Federal Reserve’s target policy rate, which anchors short-term borrowing costs across the economy.
What ARKG's Fees Cost You
ARKG charges an expense ratio of 0.75% a year, deducted automatically from the fund's value. Small percentages compound into real money — adjust the figures below to see the impact on your own numbers.
Assumes a constant gross return and no additional contributions — a simplification, but it isolates exactly what the expense ratio costs. Try the full fee calculator to model contributions and compare any two funds.
ARKG Liquidity, Domicile & Tax Treatment
Liquidity: Quoted bid/ask spread is 0.77% and average daily volume is 3.3M/day. Tighter spreads and higher volume mean lower round-trip trading costs; this is a live-market snapshot and can widen during volatile sessions. AUM of $1.73B provides ample scale, supporting tight spreads and issuer commitment to keep the fund open.
Domicile & tax treatment: ARKG is a US-domiciled, SEC-registered ('40 Act) exchange-traded fund. Dividends and capital gains distributions are reported to US investors on Form 1099-DIV, and the fund is not subject to the PFIC reporting or UCITS-specific rules that apply to Irish- or Luxembourg-domiciled funds. Non-US investors should note that US-domiciled ETFs are generally subject to 30% US withholding tax on dividends (unless reduced by treaty) and to US estate tax exposure on the position — Irish-domiciled UCITS ETFs tracking the same index often avoid both, which is why non-US residents frequently prefer the UCITS equivalent where one exists. This is general information, not tax advice — consult a tax professional for your situation.
ARKG Performance History
| Period | Return |
|---|---|
| 1-Day | -2.60% |
| 1-Week | -5.17% |
| 1-Month | -2.00% |
| 3-Month | +26.88% |
| 6-Month | +10.43% |
| YTD | +29.58% |
| 1-Year | +42.41% |
| 3-Year | -0.50% |
How ARKG Compares to Other Healthcare ETFs
| Rank | Grade | Ticker | Name | 1-Year | Exp. Ratio | AUM |
|---|---|---|---|---|---|---|
| #66 | B |
XBI | State Street SPDR S&P Biotech ETF | +71.35% | 0.35% | $10.7B |
| #69 | B |
VHT | Vanguard Health Care Index Fund ETF Shares | +23.45% | 0.09% | $20.4B |
| #92 | B |
XLV | State Street Health Care Select Sector SPDR ETF | +21.38% | 0.08% | $40.6B |
| #110 | B |
FHLC | Fidelity MSCI Health Care Index ETF | +23.55% | 0.084% | $3.22B |
| #122 | B |
XPH | State Street SPDR S&P Pharmaceuticals ETF | +57.67% | 0.35% | $428M |
| #125 | B |
IBB | iShares Biotechnology ETF | +39.29% | 0.44% | $9.09B |
| #172 | B |
PPH | VanEck Pharmaceutical ETF | +26.45% | 0.36% | $879M |
| #198 | C |
IYH | iShares U.S. Healthcare ETF | +21.01% | 0.38% | $3.16B |
| #293 | C |
IHF | iShares U.S. Healthcare Providers ETF | +30.54% | 0.38% | $1.18B |
| #389 | D |
ARKG | ARK Genomic Revolution ETF | +42.41% | 0.75% | $1.73B |
| #443 | F |
IHI | iShares U.S. Medical Devices ETF | -17.48% | 0.38% | $3.02B |